These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36567410)

  • 21. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.
    Johnson MD; O'Connell M; Pilcher W
    J Neurooncol; 2011 Feb; 101(3):441-8. PubMed ID: 20596751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas.
    Barresi V; Lionti S; La Rocca L; Caliri S; Caffo M
    Neuropathology; 2019 Feb; 39(1):22-29. PubMed ID: 30511495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
    Pellerino A; Soffietti R; Rudà R
    J Neurooncol; 2016 Mar; 127(1):201-3. PubMed ID: 26614515
    [No Abstract]   [Full Text] [Related]  

  • 27. Everolimus effectively blocks pulmonary metastases from meningioma.
    Bertolini F; Pecchi A; Stefani A; Fontana A; Rossi G
    Neuro Oncol; 2015 Sep; 17(9):1301-2. PubMed ID: 26293327
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
    Kessler RA; Garzon-Muvdi T; Yang W; Weingart J; Olivi A; Huang J; Brem H; Lim M
    World Neurosurg; 2017 May; 101():47-56. PubMed ID: 28143726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.
    Jiang J; Lin C; Liu N; Zhang Z; Sun Y; Fang X; Qi J
    APMIS; 2013 Oct; 121(10):997-1003. PubMed ID: 23879478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
    Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
    J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
    Dasanu CA; Alvarez-Argote J; Limonadi FM; Codreanu I
    Expert Opin Biol Ther; 2019 Feb; 19(2):99-104. PubMed ID: 30556741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma.
    Zhu H; Miao Y; Shen Y; Guo J; Xie W; Zhao S; Dong W; Zhang Y; Li C
    J Transl Med; 2019 Oct; 17(1):354. PubMed ID: 31665029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
    Belanger K; Ung TH; Damek D; Lillehei KO; Ormond DR
    BMC Cancer; 2022 Apr; 22(1):367. PubMed ID: 35392834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathology and genetics of meningiomas.
    Alahmadi H; Croul SE
    Semin Diagn Pathol; 2011 Nov; 28(4):314-24. PubMed ID: 22195409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
    Cimino PJ
    Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.